Clinical utility of nivolumab in the treatment of advanced melanoma
Ramsey Asmar,1 Jessica Yang,1 Richard D Carvajal1,2 1Department of Medicine, College of Physicians and Surgeons, 2Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA Abstract: Melanomas are highly immunogenic tumors that evade the immune system by exploiting innate c...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-02-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/clinical-utility-of-nivolumab-in-the-treatment-of-advanced-melanoma-peer-reviewed-article-TCRM |
id |
doaj-1808ed0704f7490b85ab6103fa2d3b34 |
---|---|
record_format |
Article |
spelling |
doaj-1808ed0704f7490b85ab6103fa2d3b342020-11-25T01:01:57ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2016-02-012016Issue 131332525762Clinical utility of nivolumab in the treatment of advanced melanomaAsmar RYang JCarvajal RDRamsey Asmar,1 Jessica Yang,1 Richard D Carvajal1,2 1Department of Medicine, College of Physicians and Surgeons, 2Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA Abstract: Melanomas are highly immunogenic tumors that evade the immune system by exploiting innate checkpoint pathways, rendering effector T-cells anergic. The immunotherapeutic approach of checkpoint inhibition can restore and invigorate endogenous antitumor T-cell responses and has become an important treatment option for patients with advanced melanoma. The CTLA-4 inhibitor ipilimumab and the PD-1 inhibitors nivolumab and pembrolizumab have been shown to induce durable responses and improve overall survival in metastatic, refractory melanoma. Optimization and validation of pretreatment biomarkers to predict response to these agents is a crucial area of ongoing research. Combination immunotherapy has recently demonstrated superior response rates compared to monotherapy; further investigation is needed to refine combinatorial strategies. Keywords: nivolumab, immune checkpoint inhibitors, PD-1, melanomahttps://www.dovepress.com/clinical-utility-of-nivolumab-in-the-treatment-of-advanced-melanoma-peer-reviewed-article-TCRMnivolumabimmune checkpoint inhibitorsPD-1melanoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Asmar R Yang J Carvajal RD |
spellingShingle |
Asmar R Yang J Carvajal RD Clinical utility of nivolumab in the treatment of advanced melanoma Therapeutics and Clinical Risk Management nivolumab immune checkpoint inhibitors PD-1 melanoma |
author_facet |
Asmar R Yang J Carvajal RD |
author_sort |
Asmar R |
title |
Clinical utility of nivolumab in the treatment of advanced melanoma |
title_short |
Clinical utility of nivolumab in the treatment of advanced melanoma |
title_full |
Clinical utility of nivolumab in the treatment of advanced melanoma |
title_fullStr |
Clinical utility of nivolumab in the treatment of advanced melanoma |
title_full_unstemmed |
Clinical utility of nivolumab in the treatment of advanced melanoma |
title_sort |
clinical utility of nivolumab in the treatment of advanced melanoma |
publisher |
Dove Medical Press |
series |
Therapeutics and Clinical Risk Management |
issn |
1178-203X |
publishDate |
2016-02-01 |
description |
Ramsey Asmar,1 Jessica Yang,1 Richard D Carvajal1,2 1Department of Medicine, College of Physicians and Surgeons, 2Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA Abstract: Melanomas are highly immunogenic tumors that evade the immune system by exploiting innate checkpoint pathways, rendering effector T-cells anergic. The immunotherapeutic approach of checkpoint inhibition can restore and invigorate endogenous antitumor T-cell responses and has become an important treatment option for patients with advanced melanoma. The CTLA-4 inhibitor ipilimumab and the PD-1 inhibitors nivolumab and pembrolizumab have been shown to induce durable responses and improve overall survival in metastatic, refractory melanoma. Optimization and validation of pretreatment biomarkers to predict response to these agents is a crucial area of ongoing research. Combination immunotherapy has recently demonstrated superior response rates compared to monotherapy; further investigation is needed to refine combinatorial strategies. Keywords: nivolumab, immune checkpoint inhibitors, PD-1, melanoma |
topic |
nivolumab immune checkpoint inhibitors PD-1 melanoma |
url |
https://www.dovepress.com/clinical-utility-of-nivolumab-in-the-treatment-of-advanced-melanoma-peer-reviewed-article-TCRM |
work_keys_str_mv |
AT asmarr clinicalutilityofnivolumabinthetreatmentofadvancedmelanoma AT yangj clinicalutilityofnivolumabinthetreatmentofadvancedmelanoma AT carvajalrd clinicalutilityofnivolumabinthetreatmentofadvancedmelanoma |
_version_ |
1715872428671893504 |